In another report, p53 null leukemia EU-4 cells coped with THP, and the result showed that THP downregulated XIAP protein by inhibiting MDM2, which is a primary cellular inhibitor of p53 and a therapy target of cancer (Wang S. et al., 2017) and is associated with proteasome-dependent pathway; hence, THP result in p53-independent apoptosis and increased the sensitivity of EU-4 cells to doxorubicin (Li S. et al., 2017). This evidence concerns the gene TP53 and cancer.